Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
Year: 2004
Type: article
Study design: Observational Study
DOI: 10.1002/pds.977
Institution: United States Food and Drug Administration
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: rhabdomyolysis, statins, gemfibrozil, statin-fibrate combination therapy, adverse drug reactions, drug safety, FDA Adverse Event Reporting System, reporting rates, cerivastatin, renal failure, creatine kinase, lipid-lowering therapy, drug interactions, post-marketing surveillance, cardiovascular risk factors
Open Access status: closed
OpenAlex ID: W2102504779
